Form 4 for STLN Starling Oncology, Inc.
Accepted 2024-12-02 00:00:00 ET · period of report 2024-11-12 · accession 0001799191-24-000063 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-12-02 | 2024-11-26+ | STLN | Hively Brad | Dir | P - Purchase | $0.1667 | +300.0K | 616.8K | +95% | +$50.0K |
| 2024-12-02 | 2024-11-12 | STLN | Hively Brad | Dir | J - Other | $0.00 | -353.4K | 366.8K | -49% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock | 2024-12-02 | P | A | 50,000 | $0.15 | 666,753 | D | — | — | (F2) 44,000 being restricted stock units that vest in full on the date of the Company's 2025 annual meeting of stockholders, subject to continued service with the Company through such vesting date. |
| 2 | Common | Common stock | 2024-11-26 | P | A | 250,000 | $0.17 | 616,753 | D | — | — | (F2) 44,000 being restricted stock units that vest in full on the date of the Company's 2025 annual meeting of stockholders, subject to continued service with the Company through such vesting date. |
| 3 | Common | Common stock | 2024-11-12 | J | D | 353,450 | $0.00 | 366,753 | D | — | — | (F1) Reflects the forfeiture of restricted earn-out shares that were unvested due to failure to meet earnout targets of the Issuer's stock price of $12.50 and $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following November 12, 2021, the date of the closing of the Business Combination, subject to continued employment at such time. |